29
/it/
it
AIzaSyAYiBZKx7MnpbEhh9jyipgxe19OcubqV5w
April 1, 2024
Creare
Public Timelines
Biblioteca
FAQ
For education
Cabinet
For educational institutions
For teachers
For students/pupils
Scaricare
Export
Creare una copia
Integrare nel sito Web
Modificare
Visualizzazioni 608
0
0
New timeline
All
è stata creata
Ariane Nicole
⟶ è stato aggiornato 4 ott 2017 ⟶
List of edits
Commenti
Eventi
Shire acquired TKT's gene activation technology, a strategy to expand into protein therapeutics
Cerezyme shortage due to viral contamination at Genzyme's MA plant
Initial availability: Patients rapidly switched to VPRIV, particularly patients with severe forms of the disease to ensure continuation of treatment
VPRIV formally launches at $170,000 for a year of therapy, 15% lower than Cerezyme's $200,000
7% drop in VPRIV sales due to Cerdelga market entry
Pfizer acquires global licensing rights (ex-Israel) from Protalix for its late stage Gaucher asset Protalix's ProCellEx technology uses plant-based cells for drug production, reducing contamination risk
At launch, Elelyso priced at $150,000 for a year of therapy, 25% lower than Cerezyme's $200,000
ISU Abxis initiates global Phase III study of Abcertin
Abcertin is launched in South Korea (approved in South Korea with same INN as imiglucerase
400 IU Abcertin is approved and launched in South Korea Abcertin is launched in Mexico
ISU Abxis signs a contract with Fara Teb Ayeen, Iran to supply Gaucher disease medicine with contract value of KRW 1.9 billion (~$1.6 billion) (one of two deals)
ISU Abxis signs a KRW 1.06 billion (~$0.9 million) contract with Laboratories PiSA SA de CV pharmaceutical company in Mexico to export Abcertin (one of three deals)
Abcertin approved in Ecuador- first country to approve Abcertin as a biosimilar
Cerezyme approved for treatment of Type 1 Gaucher disease
Cerdelga approved for treatment of Type 1 Gaucher disease
Cerezyme licensed for treatment of non- neurological manifestations of Type 3 Gaucher disease
Elelyso licensed for Type 3 Gaucher disease in Canada, specifically for hematologic manifestations in pediatric patients
Zavesca approved for Type 1 Gaucher treatment in Europe
Actelion starts launch of Zavesca in EU
Zavesca approved for Type 1 Gaucher treatment in US Zavesca is the first and only oral SRT therapy available
J&J acquires Actelion